Pegylated interferon (PEG-IFN) plus ribavirin therapy is still recommended for elderly and/or cirrhotic patients. This study examined whether sustained virological response (SVR) to low-dose PEG-IFN-α2a plus ribavirin therapy for elderly and/or cirrhotic patients could be predicted based on viral reduction within 2 weeks after therapy initiation or interleukin IL-(28B) polymorphism and viral mutations.
Methods
Participants comprised 115 elderly (≥65 years) and/or cirrhotic patients with genotype-1b and high viral load. Reduced doses of PEG-IFN-α2a (90 μg/kg/week) and ribavirin (400-800 mg/day) were administered for 48-72 weeks based on virological response of each patient.
Results
SVR was achieved in 34% (39/115), and treatment was discontinued in 15% (17/115). Univariate analysis identified age, α-fetoprotein, fibrosis marker, interferon sensitivity-determining region (ISDR), IL-28B polymorphism and level of viral reduction within 2 weeks as factors contributing significantly to SVR. However, no significant differences were noted in core amino acid substitutions. Multivariate analysis identified age, hyaluronic acid, ISDR and viral reduction as factors independently associated with SVR. Positive predictive value (PPV) and negative predictive value (NPV) of SVR based on the level of viral reduction at 2 weeks (cutoff level, 1.7 log IU/ml) were 83% and 84%, respectively. The PPV of SVR based on IL-28B major and ISDR mutant was 70%, and the NPV of SVR based on IL-28B minor and wild-type ISDR was 89%.
Conclusions
Evaluations of viral reduction at 2 weeks or both IL-28B and ISDR are useful to predict SVR to low-dose PEG-IFN-α2a plus ribavirin therapy for elderly and/ or cirrhotic patients.
References
1.
KasaharaA., HayashiN., MochizukiK.Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology1998; 27: 1394–1402.
2.
Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of Hepatology.Guidelines for the management of hepatitis C virus infection: first edition, May 2012, The Japan Society of Hepatology. Hepatol Res2013; 43: 1–34.
3.
GhanyM.G., StraderD.B., ThomasD.L., SeeffL.B.Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009; 49: 1335–1374.
4.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
5.
KumadaH., ToyotaJ., OkanoueT., ChayamaK., TsubouchiH., HayashiN.Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol2012; 56: 78–84.
6.
NudoC.G., WongP., HilzenratN., DeschenesM.Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol2006; 20: 589–592.
7.
IwasakiY., IkedaH., ArakiY.Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology2006; 43: 54–63.
8.
HiramatsuN., OzeT., TsudaN.Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?Hepatol Res2006; 35: 185–189.
9.
YamadaG., IinoS., OkunoT.Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig2008; 28: 9–16.
10.
TamaiH., ShingakiN., ShirakiT.Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. Hepatol Res2011; 41: 1137–1144.
11.
KoiralaJ., GandotraS.D., RaoS.Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat2007; 14: 782–787.
12.
EnomotoN., SakumaI., AsahinaY.Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med1996; 334: 77–81.
13.
AkutaN., SuzukiF., SezakiH.Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology2005; 48: 372–380.
14.
TanakaY., NishidaN., SugiyamaM.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet2009; 41: 1105–1109.
15.
BedossaP., PoynardT.An algorithm for the grading of activity in chronic hepatitis C. Hepatology1996; 24: 289–293.
16.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
17.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
18.
RoomerR., HansenB.E., JanssenH.L., de KnegtR.J.Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology2010; 52: 1225–1231.
19.
TamaiH., MoribataK., MoriY.Low-dose pegylated interferon-alpha-2a monotherapy in elderly and/or cirrhotic patients infected with hepatitis C virus genotype-2 or genotype-1 low level infection. Hepatol Res2013; 43: 702–708.
20.
DavisG.L., WongJ.B., McHutchisonJ.G., MannsM.P., HarveyJ., AlbrechtJ.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology2003; 38: 645–652.
21.
ReddyK.R., ShiffmanM.L., MorganT.R.Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol2007; 5: 124–129.
22.
ShiffmanM.L., GhanyM.G., MorganT.R.Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology2007; 132: 103–112.
23.
McHutchisonJ.G., MannsM., PatelK.Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology2002; 123: 1061–1069.
24.
OkanoueT., ItohY., HashimotoH.Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol2009; 44: 952–963.
25.
DienstagJ.L., McHutchisonJ.G.American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology2006; 130: 225–230.
26.
HayashiK., KatanoY., HondaT.Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver Int2011; 31: 1359–1365.
27.
BergT., von WagnerM., NasserS.Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology2006; 130: 1086–1097.
28.
PearlmanB.L., EhlebenC., SaifeeS.Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology2007; 46: 1688–1694.
29.
WatanabeS., EnomotoN., KoikeK.Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res2010; 40: 135–144.
30.
OzeT., HiramatsuN., YakushijinT.The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol2011; 46: 944–952.
31.
AkutaN., SuzukiF., HirakawaM.A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol2009; 81: 452–458.
32.
FerenciP., FriedM.W., ShiffmanM.L.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin. J Hepatol2005; 43: 425–433.
33.
ButiM., MendezC., SchaperM.Hepatitis C virus core antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol2004; 40: 527–532.
34.
GonzálezV., PadillaE., DiagoM.Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*. J Viral Hepat2005; 12: 481–487.
35.
LoggiE., CursaroC., ScuteriA.Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol2013; 56: 207–211.
